 Home > Medical News > Latest Medical News > Eli Lilly's dual agonist tirzepatide has no obvious advantage over competitor drugs!

Eli Lilly's dual agonist tirzepatide has no obvious advantage over competitor drugs!

 Last Update: 2022-05-03
 Source: Internet
 Author: User

Tags

new energy source

osco drug locations

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compilenewborn

So far, the clinical data for Eli Lilly and Co.

This is the central question of a recent Institute for Clinical and Economic Review (ICER) report on Lilly's highly promising dual-target GLP-R/GIPR agonist, tirzepatide

Tirzepatide is a novel, once-weekly dual agonist of glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory polypeptide) receptor and glucagon-like peptide-1 (GLP-1) receptor

Currently, tirzepatide is being developed to treat type 2 diabetes and obesity

In the published assessment report, ICER noted that the available data on tirzepatide "highly affirmatively" suggest that adding tirzepatide to background therapy "has at least a small and potentially substantial net health benefit"

In a head-to-head clinical trial of Ozempic, tirzepatide demonstrated greater reductions in blood sugar levels, body weight, triglycerides and blood pressure, Dr.

Based on current data, ICER believes a reasonable price for tirzepatide could be between $5,500 and $5,700 a year

Meanwhile, ICER points out that, in terms of heart health, the results of the tirzepatide trial are yet to come

Beyond diabetes, tirzepatide could eventually also compete with Novo Nordisk's Wegovy in obesity

Source: Lilly's tirzepatide doesn't necessarily top diabetes rivals Jardiance and Ozempic, ICER says

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.